Heterogeneity of type 1 diabetes mellitus;Heterogeneidade do diabetes melito tipo 1

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 52, Issue 2, 2008, Pages 205-218

  Dib, Sergio Atala ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Heterogeneity; Type 1 diabetes mellitus

Indexed keywords

AUTOIMMUNE REGULATOR PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HLA DR ANTIGEN; TRANSCRIPTION FACTOR;

AUTOIMMUNE POLYENDOCRINOPATHY; CLASSIFICATION; DIABETIC KETOACIDOSIS; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROTEIN LOSING GASTROENTEROPATHY; REVIEW; SYNDROME; X CHROMOSOME LINKED DISORDER;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; FORKHEAD TRANSCRIPTION FACTORS; GENETIC DISEASES, X-LINKED; GENETIC PREDISPOSITION TO DISEASE; GLUCOSEPHOSPHATE DEHYDROGENASE; HLA-DR ANTIGENS; HUMANS; MUTATION; POLYENDOCRINOPATHIES, AUTOIMMUNE; PROTEIN-LOSING ENTEROPATHIES; SYNDROME; TRANSCRIPTION FACTORS;

EID: 43249083193     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302008000200008     Document Type: Review

References (88)

1. Eisenbarth GS. Update in type 1 diabetes. J Clin Endocrinol Metab. 2007;92(7):2403-7.
2. Barker JM. Clinical review: type 1 diabetes-associated autoimmunity: natural history, genetic associations and screening. J Clin Endocrinol Metab. 2006;91(4):1210-7.
3. Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, Colman PG. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care. 2006;29(5):970-5.
4. Su MA, Anderson MS. Aire: an update. Curr Opin Immunol. 2004;16:746-52.
5. Wildin RS, Freitas A. IPEX and FOXP3: clinical and research perspectives. J Autoimmun. 2005;25:(Suppl):56-62.
6. Hagopian WA, Sanjeevi CB, Kockum I, Landin-Olsson M, Karlsen AE, Sundkist G, et al. Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children. J Clin Invest. 1995;95:1505-11.
7. Maldonado M, Hampe CS, Gaur L, D'Amico S, Iyer D, Hammerle LP, et al. Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functional classification, prospective analysis and clinical outcomes. J Clin Endocrinol Metab. 2003; 88(11):5090-8.
8. Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, et al. Fulminant type 1 diabetes a nationwide survey in Japan. Diabetes Care. 2003;26(8):2345-52.
9. 8a. Molven A, Ringdal M, Nordbo AM, Rader H, Stay J, Lipkind GM, et al. Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. Diabetes. 2008. Jan 11. (Epub ahead of print)
10. American Diabetes Association. Type 2 diabetes in children and adolescents. American Diabetes Association. Diabetes Care. 2000;23:381-9.
11. Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, et al. A risk score for type 1 diabetes derived from autoantibody positive participants in the diabetes prevention trial - type 1. Diabetes Care. 2007. Publish ahead of print, published online December 4.
12. Libman IM, Becker DJ. Coexistence of type 1 and type 2 diabetes mellitus: "double" diabetes? Pediatr Diabetes. 2003;4:110-3.
13. Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M, et al. Positional cloning of the APECED gene. Nat Genet. 1997;17:393-8.
14. Björses P, Pelto-Huikko M, Kaukonen J, Aaltonen J, Peltonen L, Ulmanen I. Localization of the APECED protein in distinct nuclear structures. Hum Mol Genet. 1999;8:259-66.
15. Meager A, Visvalingam K, Peterson P, et al. Anti-interferon antibodies in autoimmune polyendocrine syndrome type 1. Plos Medicine. 2006;3:e289.
16. Notkins AL, Lernmark Å. Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest. 2001;108:1247-52.
17. Gylling M, Tuomi T, Björses P, Kontiainen S, Partanen J, Christie MR, et al. Beta-cell autoantibodies, human leukocyte antigen II alleles, and type 1 diabetes in autoimmune polyendocrinopathycandidiasis - ectodermal dystrophy. J Clin Endocrinol Metab. 2000;85:4434-40.
18. Powell BR, Buist NR, Stenzel P. An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. J Pediatr. 1982;100:731-7.
19. Godfrey VL, Wilkinson JE, Russel LB. X-linked lymphoreticular disease in the scurfy (SF) mutant mouse. Am J Pathol. 1991;138:1379-87.
20. Chatila TA, Blaeser F, Ho N, et al. JM2, enconding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest. 2000;106:R75-R81.
21. Walker MR, Kasprowicz DJ, Gersuk VH, et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest. 2003;112:1437-43.
22. Baud O, Goulet O, Canioni D, et al. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogenic bone marrow transplantation. N Engl J Med. 2001;344:1758-62.
23. Bindl L, Torgerson T, Perroni L, et al. Successful use of the new immunesupressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-lonked syndrome). J Pediatr. 2005;147:256-9.
24. Bingley PJ, Bonifacio E, Williams AJK, Genovese S, Bottazzo GF, Gale EAM. Prediction on IDM in the general population; strategies based on combinations of autoantibody markers. Diabetes 1997:46:1701-10.
25. Tiberti C, Buzzetti R, Anastasi E, Dotta F, Vestal M, Petrone A, et al. Autoantibody negative new onset type 1 diabetic patients lacking high risk HLA alleles in a Caucasian population: are type1b diabetes cases? Diabetes Metab Res Rev. 2000;16:8-14.
26. Wang J, Miao D, Babu S, Yu J, Barker J, Klingensmith G, et al. Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab. 2007;92(1):88-92.
27. Wenzlau JM, Juhl K, Yu L, Moua O, Sarka SA, Gottlieb P, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. PNAS. 2007; 104(43):17040-5.
28. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDM study group. N Engl J Med. 2000;342:301-7.
29. Wakisaka M, Nunoi K, Wada M, et al. Two cases of abrupt onset type 1 diabetes associated with elevation of elastase 1 and diabetic ketoacidosis. J Jpn Diab Soc. 1987;30:619-24.
30. Kawasaki E, Matsura N, Eguchi K. Type 1 diabetes in Japan. Diabetologia. 2006;49(5):828-36.
31. Sayama K, Imagawa A, Okita K, Uno S, Moriwaki M, Kozawa J, et al. Pancreatic beta and alpha cells are both decreased in patients with fulminant type 1 diabetes: a morphometrical assessment. Diabetologia. 2005;48:1560-4.
32. Imagawa A, Hanafusa T, Uchigata Y, et al. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care. 2003;26:2345-52.
33. Kawasaki E, Eguchi K. Is type 1 diabetes in the Japanese population the same as among Caucasians? Ann NY Acad Sci. 2004;1037:96-103.
34. Kotani R, Nagata M, Imagawa A, et al. T lymphocyte response against pancreatic beta cell antigens in fulminant type 1 diabetes. Diabetologia. 2004;47:1285-91.
35. Tanaka S, Kobayashi T, Momotsu T. A novel subtype of type 1 diabetes mellitus. N Engl J Med. 2000;342:1835-7.
36. Sekine N, Motokura T, Oki T, et al. Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome. JAMA. 2001;285:1153-4.
37. Nagaoka T, Terada M, Miyakoshi H. Insulin-dependent diabetes mellitus following acute pancreatitis caused by herpes simplex virus: a case report. J Jpn Diab Soc. 2001;44:335-40.
38. Imagawa A, Hanafusa T, Makino H, Miyagawa JI, Juto P. High titres of IgA antibodies to enterovirus in fulminant type-1 diabetes. Diabetologia. 2005;48:290-3.
39. Winter WE, Maclaren NK, Riley WJ, et al. Maturity-onset diabetes of youth in black Americans. N Engl J Med. 1987;316:285-91.
40. Banerji MA, Chaiken RL, Huey H, Tuomi T, Norin AJ, Mackay IR, et al. GAD antibody negative NIDM in adult black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4: Flatbush diabetes. Diabetes. 1994;43:741-5.
41. Pinero-Pilona A, Litonjua P, Aviles-Santa L, Raskin P. Idiopathic type 1 diabetes in Dallas, Texas: a 5-year experience. Diabetes Care. 2001;24:1014-8.
42. Mauvais-Jarvis F, Sobngwi E, Porcher R, Riveline J-P, Kevorkian J-P, Vaisse C, et al. Ketosis-prone type 2 diabetes in patients of sub-saharan african origin clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance. Diabetes. 2004;53:645-53.
43. Tanaka K, Moriya T, Kanamori A, Yajima Y. Analysis and a long-term follow-up of ketosis-onset Japanese NIDM patients. Diabetes Res Clin Pract. 1999;44:137-46.
44. Tan KC, Mackay IR, Zimmet PZ, Hawkins BR, Lam KS. Metabolic and immunologic features of Chinese patients with atypical diabetes mellitus. Diabetes Care. 2000;23:335-8.
45. Aguilera E, Casamitjana R, Ercilia G, Oriola J, Gomes R, Conget I. Adult-onset atypical (type 1) diabetes. Additional insights and differences with type 1A diabetes in a European Mediterranean population. Diabetes Care. 2004;27:1108-14.
46. Rodacki M, Zajdenverg L, Lima GAB, Nunes RC, Milech A, Oliveira JEP. Relato de caso: Diabetes flatbush - cetoacidose ao tratamento não farmacológico - Diabetes ketosis prone. Arq Bras Endocrinol Metab. 2007;51(1):131-5.
47. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-97.
48. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.
49. Pinero-Pilona A, Litonjua P, Aviles-Santa L, Raskin P. Idiopathic type 1 diabetes in Dallas, Texas: a 5-year experience. Diabetes Care. 2001;24:1014-8.
50. Beutler E. G6PD deficiency. Blood. 1994;84:3613-36.
51. Monte Alegre S, Saad ST, Delatre E, Saad MJ. Insulin secretion in patients deficient in glucose-6-phosphate dehydrogenase. Horm Metab Res. 1991;23:171-3.
52. Balasubramanyam A, Gaza G, Rodriguez L, Hampe CS, Gaur L, Lernmark A, et al. Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care. 2006;29:2575-9.
53. Mathis D, Vence L, BenoistC. Beta-cell death during progression to diabetes. Nature. 2001;414:792-8.
54. Poitout P, Robertson PR. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocrine Reviews. 2007; First published ahead of print November 29.
55. Borg H, Gottsater A, Fernlund P, Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes. 2002;51:1754-62.
56. Umpierrez GE, Kelly JP, Navarrete JE, Casals MC, Kitabchi AE. Hyperglycemic crises in urban blacks. Arch Intern Med. 1997;157:669-75.
57. Sobngwi E, Gautier JF. Adult-onset idiopathic type I or ketosisprone type II diabetes: evidence to revisit diabetes classification. Diabetologia. 2002;45:283-5.
58. Teupe B, Bergis K. Epidemiological evidence for "double diabetes". Lancet. 1991;337(9):361-2.
59. Libman IM, Becker DJ. Coexistence of type 1 and type 2 diabetes mellitus: "double" diabetes? Pediatr Diabetes. 2003;4:110-3.
60. Hathout EH, Thomas W, El-Shahawy M, Nahab F, Mace JW. Diabetic autoimmune markers in children and adolescents with type 2 diabetes. Pediatrics. 2002;107(6):1-4.
61. Reinehr T, Schober E, Wiegand S, Thon A, Holl R. On behalf of the DPV-wiss study group. Beta-cell autoantibodies in children with type 2 diabetes mellitus: subgroup or misclassification? Arch Dis Child. 2006;91:473-7.
62. Vadacca M, Valeri C, Gigante A, Guglielmi C, Pozzilli P. Action LADA group. Gender differences and the metabolic syndrome in patients with type 2 diabetes with or without autoantibodies to glutamic acid decarboxilase (GAD). Diabetes. 2006;55(Suppll. 1)Abst.1204-P, A283.
63. Brooks-Worrell BM, Greenbaum CJ, Palmer JP, Pihoker C. Autoimmunity to islet proteins in children diagnosed with newonset diabetes. J Clin Endocrinol Metab. 2004(89):2222-7.
64. Bisikirska BC, Herold KC. Regulatory T cell and type 1 diabetes. Curr Diab Rep. 2005;5:104-9.
65. Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J. 2001;15:2099-111.
66. Federici M, et al. The common Arg972 polymorphism in insulin receptor substrate-1 causes apoptosis of human pancreatic islets. FASEB J. 2001;15:22-4.
67. Altshuler D, et al. The common PPARg Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000;26:76-80.
68. Grant SFA, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38:320-3.
69. Field SF, Howson JMM, Smyth DJ, Walker NM, Dunger DB, Todd JA. Analysis of the type 2 diabetes gene, TCF7L2, in 13,795 type 1 diabetes cases and control subjects. Diabetologia. 2007;50:212-3.
70. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889-94.
71. Field SF, Howson JMMM, Walker NM, Dunger DB, Todd JA. Analysis of the obesity gene FTO in 14,803 type 1 diabetes cases and controls. Diabetologia. 2007;50(10):2218-20.
72. Dahlquist GG. Environmental risk factors in human type1 diabetes - an epidemiological perspective. Diabetes Metab.1995;11:37-46.
73. Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia. 2001;44:914-22.
74. Dabelea D, et al. Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes. Diabetes Care. 2006;29:290-4.
75. Tsai EB, Sherry NA, Palmer JP, Herold KC. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia. 2006;49:261-70.
76. Gale EAM. To boldly go - or to go too boldly? The accelerator hypothesis revisited. Diabetologia. 2007;50:1571-5.
77. Aldhahi W, Hamdy O. Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep. 2003;3:293-8.
78. Lord G. Role of leptin in immunology. Nutr Rev. 2002;60:S35-S38.
79. Matarese G, et al. Leptin in immunology. J Immunol. 2005;174:3137-42.
80. Weisberg SP, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112: 1796-808.
81. Wachlin G, et al. IL-1b, IFN-b and TNF-a increase vulnerability of pancreatic β cells to autoimmune destruction. J Autoimmun. 2003;20:303-12.
82. Rolandsson O, et al. Glutamate decarboxylase (GAD65) and tyrosine phosphatase-like protein (IA-2) autoantibodies index in a regional population is related to glucose intolerance and body mass index. Diabetologia. 1999;42:555-9.
83. Donath MY, Halban PA. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia. 2004;47:581-9.
84. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes. Diabetologia. 2005;48:1038-50.
85. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger, J, Rocchini AP, et al. Drug therapy of high - risk lipid abnormalities in children and adolescents. A scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing. Circulation. 2007;115:1948-67.
86. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes "double diabetes" in the diabetes control and complications trial. Diabetes Care. 2007;30:707-12.
87. Pires AC, Cordeiro JA, Gabbay MAL, Giuffrida FMA, Gomes MB, DibSA. Prevalence of metabolic syndrome in young type 1 diabetes: do we need a specific criterion? Diabetes. 2006;55(Suppl1):abstract 1774 - P.A410.
88. Dib SA. Síndrome metabólica no diabetes melito do tipo 1 [tese de livre docência]. São Paulo: Universidade Federal de São Paulo. Escola Paulista de Medicina, 2006.